X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

NRG Earns £2.68m Grant Boost For Neurodegenerative Illness

Content Team by Content Team
1st June 2022
in Manufacturing, Middle East and South Asia, News
The Falling Graph of Dose Contract Manufacturing

NRG Therapeutics, a neuroscience firm, has been presented with the Biomedical Catalyst award. The £2.68 million package will be used to advance the pre-clinical development of the company’s innovative small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neuron disease (MND), and other debilitating neurodegenerative diseases.

The funding, which is partially sponsored by the government-backed body Innovate UK, will cover a 24-month study that will begin this month. NRG uses cutting-edge mitochondrial biology to provide first-in-class treatments. Its strategy is focused on blocking the mitochondrial permeability transition hole in brain cells, which has been shown to be effective in numerous Parkinson’s and MND preclinical models.

Mitochondria are the ‘batteries’ of cells that keep them running, but a growing body of research suggests that mitochondrial breakdown is widespread in many degenerative disorders. NRG’s experimental novel medications have been shown to suppress brain cell death in vitro. If the experiment is successful, it will be the first disease-modifying drug to stop or decrease the advancement of Parkinson’s disease in people who are presently solely treated for symptoms.

What has limited the drug companies from exploring mPTP inhibitors as novel therapeutic treatments to date has been the poor central nervous system insertion of known mPTP inhibitors, said Director- Research at Parkinson’s UK as well as a board member of NRG Therapeutics, Dr. Arthur Roach.

The micro compounds developed by NRG are the first orally available and CNS-permeable inhibitors of mPTP. He added that they are delighted to assist NRG in translating its exciting discoveries into innovative pharmacological treatments that have the potential to enhance the lives of people living with Parkinson’s disease.

The funding from Innovate UK comes after generous donations from Parkinson’s Virtual Biotech, Parkinson’s UK’s drug development arm, and also The Michael J. Fox Foundation. Parkinson’s disease affects around six million people worldwide and is the fastest growing neurologic ailment.

Previous Post

EMA guidance supports development of new antibiotics

Next Post

FDA Grants Novartis Cell Therapy For Follicular Lymphoma

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

FDA Grants Novartis Cell Therapy For Follicular Lymphoma

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In